DAN:NYSEDana Incorporated Analysis
Data as of 2026-08-08 - not real-time
$28.44
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Dana Incorporated is priced at $28.44, and its moving averages give no clean directional read — the structure is neutral. Relative strength is 54.2 — neutral — and the MACD signal is bullish. Price has been bracketed by support at $25.78 and resistance at $30.44.
Multiples put this in undervalued territory at a P/E of 7.3. Sell-side targets cluster 34.1% above the current quote. Revenue is growing at 3.9% on a 14.6% profit margin. The 1.69% dividend yield looks stretched against payout coverage.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 44.7%, a beta of 1.29 and a maximum drawdown of 36.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.
Multiples put this in undervalued territory at a P/E of 7.3. Sell-side targets cluster 34.1% above the current quote. Revenue is growing at 3.9% on a 14.6% profit margin. The 1.69% dividend yield looks stretched against payout coverage.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 44.7%, a beta of 1.29 and a maximum drawdown of 36.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.
Top Market Events
Dana Incorporated NYSE: DAN today announced its second-quarter 2026 financial results, delivering strong performance,...Dana Incorporated NYSE:DAN is included among Billionaire Mario Gabelli’s Top 12 Dividend Stocks.On June 12, Wells Fargo lowered its price recommendation on Dana Incorporated NYSE:DAN to $33 from $36.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 29.19
- MACD momentum is positive
- 30-day volatility of 44.7%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Dividend yield of 1.69% looks stretched against payout coverage
- Trading below the 200-day average of 29.19
- Analyst targets imply +34.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- Dividend yield of 1.69% looks stretched against payout coverage
- Analyst targets imply +34.1% versus the current price
- Negative return on equity of -1.6%
Key Metrics & Analysis
Financial Health
Revenue Growth3.90%
Profit Margin14.55%
P/E Ratio7.3
ROE-1.63%
ROA2.80%
Debt/Equity75.79
P/B Ratio1.6
Op. Cash Flow$431.0M
Free Cash Flow$631.2M
Technical Analysis
TrendNeutral
RSI54.2
Support$25.78
Resistance$30.44
MA 20$27.31
MA 50$29.26
MA 200$29.19
MACDBullish
VolumeIncreasing
Fear & Greed Index94.82
Valuation
Fair Value$77.90
Target Price$38.14
Upside/Downside34.12%
GradeUndervalued
TypeBlend
Dividend Yield1.69%
Risk Assessment
Beta1.29
Volatility44.74%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.